| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6091061 | Clinical Gastroenterology and Hepatology | 2016 | 37 Pages |
Abstract
In a placebo-controlled study of patients with polycystic kidney and liver disease, 3 years of treatment with octreotide LAR significantly reduced liver volume; reductions were maintained for 2 years after treatment ended. Octreotide LAR was well-tolerated. ClinicalTrials.gov number: NCT02119052.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Antonio Pisani, Massimo Sabbatini, Massimo Imbriaco, Eleonora Riccio, Nadia Rubis, Anna Prinster, Annalisa Perna, Raffaele Liuzzi, Letizia Spinelli, Michele Santangelo, Giuseppe Remuzzi, Piero Ruggenenti,